To quantify the direct out‐of‐pocket patient co‐payments and time opportunity costs (length of hospital stay) incurred by Indigenous and non‐Indigenous persons diagnosed with cancer during the first year postdiagnosis. CancerCostMod was used, ...
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=O113482896
2019년
-
1743-7555
1743-7563
SCOPUS;SCIE
학술저널
309-315 [※수록면이 p5 이하이면, Review, Columns, Editor's Note, Abstract 등일 경우가 있습니다.]
0
상세조회0
다운로드다국어 초록 (Multilingual Abstract)
To quantify the direct out‐of‐pocket patient co‐payments and time opportunity costs (length of hospital stay) incurred by Indigenous and non‐Indigenous persons diagnosed with cancer during the first year postdiagnosis. CancerCostMod was used, ...
To quantify the direct out‐of‐pocket patient co‐payments and time opportunity costs (length of hospital stay) incurred by Indigenous and non‐Indigenous persons diagnosed with cancer during the first year postdiagnosis.
CancerCostMod was used, which is a model of cancer costs based upon a whole‐of‐population data linkage. The base population was a census of all persons diagnosed with cancer in Queensland, Australia between 1 July 2011 and 30 June 2012 (n = 25,553). Individual records were linked to corresponding Queensland Health Admitted Patient Data Collection, Emergency Data Information System, Medicare Benefits Schedule, and Pharmaceutical Benefits Scheme records between 1 July 2011 and 30 June 2015. Queensland data were weighted to be representative of the Australian population (approximately 123,900 Australians, 1.7% Indigenous Australians).
After adjusting for age, sex, rurality, area‐based deprivation, and cancer group, Indigenous Australians accrued significantly less in postdiagnosis patient co‐payments at 0–6 months (61% less) and 7–12 months (63% less). Indigenous Australians also had significantly fewer postdiagnosis hospitalizations at 0–6 months (21% fewer) and 7–12 months (27% fewer).
There is growing concern regarding the financial burden of cancer to the patient. The time spent away from family and their community may also have an important time opportunity cost, which may affect a person's decision to undertake or continue treatment. This is the first study in Australia to identify the financial cost of co‐payments for Indigenous people with cancer, as well as the number and length of hospitalizations as drivers of time opportunity costs.